|
| Press Releases |
|
 |
|
| Wednesday, September 15, 2021 |
|
|
Hua and Sinopharm Announced Supply Chain Strategic Cooperation |
| On September 13, 2021, Hua Medicine (Shanghai) Ltd. (the "Hua Medicine", Stock Code: 2552.HK) has signed a supply chain strategic cooperation agreement with Sinopharm Group Co., Ltd. (the "Sinopharm", Stock Code: 1099). more info >> |
|
| Thursday, August 19, 2021 |
|
|
Hua Medicine Announces 2021 Interim Results |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announces the consolidated results of the Company and its subsidiaries for the six months ended June 30, 2021 (the "Reporting Period"). more info >> |
|
| Friday, April 23, 2021 |
|
|
Hua Medicine Announces Acceptance of a New Drug Application for Dorzagliatin in China - First Glucokinase Activator (GKA) Globally |
| Hua Medicine (the "Company", Stock Code: 2552.HK), today announced that the New Drug Application (NDA) for dorzagliatin for the treatment of Type 2 Diabetes (T2D) was accepted by the China National Medical Products Administration (NMPA). more info >> |
|
| Friday, March 19, 2021 |
|
|
Milestone Development Achieved in Clinical Trials and Commercialization, Hua Medicine's Dorzagliatin Readying for NDA Submission |
| Hua Medicine (2552.HK), today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2020 (the "Reporting Period"). more info >> |
|
| Friday, December 18, 2020 |
|
|
Hua Medicine Completes Registration Phase III Trials; Announces 52-Week Result for DAWN (HMM0302), Dorzagliatin's Phase III Combination with Metformin Trial |
| Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced: more info >> |
|
| Wednesday, October 14, 2020 |
|
|
Hua Medicine Announces the Drug Manufacturing Permit Granted for Dorzagliatin |
Hua Medicine (the "Company", Stock Code: 2552.HK) announces that, after review and on-site verification under the Marketing Authorization Holder ("MAH") system, the Company has obtained the drug manufacturing permit for dorzagliatin, its investigational first-in-class drug, issued by the Shanghai Municipal Drug Administrative Bureau.
more info >> |
|
| Monday, August 17, 2020 |
|
|
Bayer and Hua Medicine announce commercialization agreement and strategic partnership for investigational first-in-class novel diabetes treatment dorzagliatin in China |
| Bayer and Hua Medicine, a leading innovative drug development company, today announced a commercialization agreement and strategic partnership for dorzagliatin, a novel diabetes treatment, in China. more info >> |
|
| Wednesday, July 1, 2020 |
|
|
Hua Medicine Announces Positive 24-Week Topline Results of Phase III Metformin Combination Trial of Dorzagliatin |
| Hua Medicine today announced the positive 24-week top-line results from HMM0302, a Phase III registration trial in China of its global first-in-class glucokinase activator dorzagliatin add-on to metformin, a first line oral antidiabetic therapy in Type 2 diabetes. more info >> |
|
| Thursday, June 18, 2020 |
|
|
Hua Medicine Successfully Completes SEED (HMM0301), Dorzagliatin Phase III Monotherapy Trial |
| Hua Medicine (the "Company", Stock Code: 2552.HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, today announced topline results from SEED (also known as HMM0301) more info >> |
|
| Monday, April 27, 2020 |
|
|
Hua Medicine Announces Positive Results in the Combination Study of Dorzagliatin with Empagliflozin (a SGLT-2 inhibitor) |
| Hua Medicine (the "Company", Stock Code: 2552. HK) today announces the positive results of the clinical study HMM0112. more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
2025 Toys & Games Fair, Baby Products Fair, Stationery & School Supplies Fair open today
Jan 6, 2025 22:40 HKT/SGT
|
|
|
Spectral Achieves Major Patent Milestone Related to Quantum Computing 
Jan 6, 2025 22:37 HKT/SGT
|
|
|
Toyota to Share Progress on Woven City at CES 2025
Jan 6, 2025 15:49 JST
|
|
|
Mazda to build Module Pack Plant for Cylindrical Lithium-ion Batteries for Automotive Use in Iwakuni City, Yamaguchi Prefecture
Jan 6, 2025 15:36 JST
|
|
|
AI Connect to Launch Revolutionary AI Agent, Redefining Financial and Technological Innovation
Jan 6, 2025 14:00 HKT/SGT
|
|
|
Celebrate Chinese New Year 2025 with Spritzer: Embrace Heartfelt & Refreshing Moments
Jan 6, 2025 12:00 HKT/SGT
|
|
|
Galaxy Payroll Group Limited and People Intelligence Singapore Pte. Ltd. Announce Strategic Partnership
Jan 3, 2025 20:41 JST
|
|
|
Combat Holiday Stress and Protect Your Immunity with LAC This Christmas!
Jan 3, 2025 10:00 HKT/SGT
|
|
|
Veganuary for Pets
Jan 3, 2025 07:00 HKT/SGT
|
|
|
Asia's Flagship Toy Fair Kicks Off 2025 Trade Shows
Jan 2, 2025 18:37 HKT/SGT
|
|
|
SPRG Steps Confidently into its 30th Year of Development
Jan 2, 2025 16:58 HKT/SGT
|
|
|
Everest Medicines Announces the Implementation of NEFECON National Reimbursement Drug List Pricing in China for the Treatment for IgA Nephropathy
Jan 2, 2025 10:52 HKT/SGT
|
|
|
AEM Appoints Chief Financial Officer
Jan 2, 2025 08:40 HKT/SGT
|
|
|
Capital Revo Receives Prestigious Industry Award for Excellence in Financial Services
Jan 1, 2025 07:00 HKT/SGT
|
|
|
Atlas Lithium Accelerates Production Readiness with Key Executive Appointments
Dec 31, 2024 07:45 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
